MX390823B - Metodo basado en celulas para determinar la potencia de la defibrotida. - Google Patents

Metodo basado en celulas para determinar la potencia de la defibrotida.

Info

Publication number
MX390823B
MX390823B MX2017006970A MX2017006970A MX390823B MX 390823 B MX390823 B MX 390823B MX 2017006970 A MX2017006970 A MX 2017006970A MX 2017006970 A MX2017006970 A MX 2017006970A MX 390823 B MX390823 B MX 390823B
Authority
MX
Mexico
Prior art keywords
defibrotide
potency
cell
determining
based method
Prior art date
Application number
MX2017006970A
Other languages
English (en)
Other versions
MX2017006970A (es
Inventor
Claudio Verga
Terenzio Ignoni
Vijay Kumar
Original Assignee
Gentium S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390823(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentium S R L filed Critical Gentium S R L
Publication of MX2017006970A publication Critical patent/MX2017006970A/es
Publication of MX390823B publication Critical patent/MX390823B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos basados en células para determinar la actividad biológica de la defibrotida. En particular, la invención proporciona un método para evaluar la potencia de la defibrotida mediante la evaluación de la viabilidad de las células de mamífero en presencia de al menos un agente citotóxico y una o más concentraciones de defibrotida. Tales métodos son particularmente útiles para la estandarización de composiciones farmacéuticas que comprenden defibrotida.
MX2017006970A 2014-11-27 2015-11-23 Metodo basado en celulas para determinar la potencia de la defibrotida. MX390823B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195277.0A EP3026122A1 (en) 2014-11-27 2014-11-27 Cellular-based method for determining the potency of defibrotide
PCT/EP2015/077355 WO2016083297A1 (en) 2014-11-27 2015-11-23 Cellular-based method for determining the potency of defibrotide

Publications (2)

Publication Number Publication Date
MX2017006970A MX2017006970A (es) 2018-03-01
MX390823B true MX390823B (es) 2025-03-21

Family

ID=52000693

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006970A MX390823B (es) 2014-11-27 2015-11-23 Metodo basado en celulas para determinar la potencia de la defibrotida.
MX2022003399A MX2022003399A (es) 2014-11-27 2017-05-26 Metodo basado en celulas para determinar la potencia de la defibrotida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003399A MX2022003399A (es) 2014-11-27 2017-05-26 Metodo basado en celulas para determinar la potencia de la defibrotida.

Country Status (19)

Country Link
US (3) US10393731B2 (es)
EP (4) EP3026122A1 (es)
JP (3) JP6700276B2 (es)
KR (2) KR20220104070A (es)
CN (1) CN107109458B (es)
AU (2) AU2015352743B2 (es)
BR (1) BR112017011012B1 (es)
CA (1) CA2968608C (es)
DK (2) DK3120153T3 (es)
ES (2) ES2972368T3 (es)
FI (1) FI3748358T3 (es)
IL (2) IL252484B (es)
MX (2) MX390823B (es)
PL (1) PL3120153T3 (es)
PT (1) PT3120153T (es)
RU (1) RU2729628C2 (es)
SG (1) SG11201704015RA (es)
WO (1) WO2016083297A1 (es)
ZA (1) ZA201703385B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN111796086A (zh) * 2020-07-03 2020-10-20 同济大学 一种个人护理品急慢性剂量-效应关系表征方法
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170215B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US4693134A (en) 1985-06-20 1987-09-15 Excelermatic Inc. High-powered vehicle drive train
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
IT1223322B (it) 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
CA2206496A1 (en) 1994-11-30 1996-06-06 Chugai Seiyaku Kabushiki Kaisha Thrombocytotic factor
WO1998001151A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
AU754242B2 (en) 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
ES2251134T3 (es) 1999-06-08 2006-04-16 Gentium S.P.A. Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1334113A4 (en) 2000-10-20 2007-08-08 Expression Diagnostics Inc EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL
AU1788502A (en) * 2000-11-28 2002-06-11 Univ Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EP1406930A4 (en) 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
CA2487171A1 (en) 2002-05-31 2003-12-11 Klinikum Der Universitat Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
WO2004003166A2 (en) 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
CA2501719C (en) 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US7723127B2 (en) * 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
AU2006222045B2 (en) 2005-03-03 2011-10-20 Gentium Spa Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
CA2692604A1 (en) * 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
CN101301306A (zh) 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防休克药物中的应用
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2637672B1 (en) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
TW201909904A (zh) 2017-08-03 2019-03-16 愛爾蘭商爵士製藥愛爾蘭有限責任公司 高濃度調配物
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations

Also Published As

Publication number Publication date
BR112017011012B1 (pt) 2024-01-16
RU2017122187A (ru) 2018-12-28
US20230194502A1 (en) 2023-06-22
EP3748358A1 (en) 2020-12-09
SG11201704015RA (en) 2017-06-29
KR20170094790A (ko) 2017-08-21
US12584903B2 (en) 2026-03-24
FI3748358T3 (fi) 2024-02-14
IL277068A (en) 2020-10-29
US10393731B2 (en) 2019-08-27
CA2968608C (en) 2023-09-05
PT3120153T (pt) 2020-10-20
EP3748358B1 (en) 2023-12-27
EP4368990A2 (en) 2024-05-15
JP6700276B2 (ja) 2020-05-27
MX2017006970A (es) 2018-03-01
IL252484A0 (en) 2017-07-31
AU2020250225A1 (en) 2020-11-05
ES2972368T3 (es) 2024-06-12
EP3120153B1 (en) 2020-08-19
CA2968608A1 (en) 2016-06-02
EP3026122A1 (en) 2016-06-01
IL252484B (en) 2020-09-30
US20200057051A1 (en) 2020-02-20
EP4368990A3 (en) 2024-08-07
DK3120153T3 (da) 2020-11-09
JP2017535277A (ja) 2017-11-30
US20170322199A1 (en) 2017-11-09
KR20220104070A (ko) 2022-07-25
MX2022003399A (es) 2022-04-18
EP3120153A1 (en) 2017-01-25
AU2020250225B2 (en) 2022-06-30
BR112017011012A2 (pt) 2018-02-14
JP2020058360A (ja) 2020-04-16
CN107109458A (zh) 2017-08-29
RU2017122187A3 (es) 2019-01-17
PL3120153T3 (pl) 2021-02-08
KR102421677B1 (ko) 2022-07-18
DK3748358T3 (da) 2024-02-26
NZ731825A (en) 2024-02-23
ES2831834T3 (es) 2021-06-09
AU2015352743A1 (en) 2017-06-08
RU2729628C2 (ru) 2020-08-11
AU2015352743B2 (en) 2020-10-15
IL277068B (en) 2021-10-31
ZA201703385B (en) 2018-08-29
WO2016083297A1 (en) 2016-06-02
JP2022160596A (ja) 2022-10-19
CN107109458B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
MX2018003353A (es) Terapias con celulas cart con una eficacia mejorada.
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
UA114901C2 (uk) Інгібітори асс та їх застосування
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EP4368728A3 (en) Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
BR112016015105A2 (pt) Conjugados var2csa-droga
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
MX2018002849A (es) Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.
GB2531213A (en) Systems and methods for high throughput analysis of conformation in biological entities
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
MX386916B (es) Partículas de proteína porosas como portadoras para activos.
BR112018004474A2 (pt) posicionamento de e911 por intermédio de rastreamento de sinal de fundo
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.